

CTLA4 & CD274

Research Grade Erfonrilimab

Catalog No.	DHJ70114A DHJ70114B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, KN-046, KN046, CAS: 2367013-69-0		
Description:	Research Grade Erfonrilimab is a bispecific humanized monoclonal antibody directed against human Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) and Programmed cell death 1 ligand 1 (PD-L1, CD274)		
UniProt ID (target):	P16410 & Q9NZQ7		
Target:	Human CTLA-4 (CD152) and PD-L1 (CD274)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human Single Domains (VH-VH'-CH), IgG1na;na		
Formulation:	Sterile-filtered 0.01 M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Erfonrilimab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

